logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Arranca el primer ensayo en humanos de una vacuna Covid-19 en España

Janssen’s coronavirus vaccine will be tested in 190 Spanish volunteers and the study will last between 4 and 6 months

Source: www.redaccionmedica.com

Spain begins, this week, the first clinical trial for the covid vaccine in phase 2, in humans, which is being developed by the pharmaceutical company Janssen in the Madrid hospitals of La Paz and La Princesa, and in the Marqués de Valdecilla de Santander. Janssen’s vaccine will be tested in 190 volunteers from two groups, one aged 18 to 55 and one aged 65 and over, and this phase 2 trial will last between four and six months.

As reported by Efe, the Madrid hospitals La Paz and La Princesa have delayed until next Tuesday the 15th the start of the clinical trial of the vaccine – scheduled for this Monday – due to a “problem” with the laboratory. Meanwhile, the Marqués de Valdecilla de Santander hospital, included in the study, will begin the trial on the scheduled date.

In La Paz and La Princesa, 75 volunteers have been selected and 40 in Santander, who will begin to provide the first doses to all study participants from this Monday until September 22. Being healthy, not having had the covid and accepting conditions for a clinical trial have been the requirements of these volunteers to test the vaccine.

The pharmaceutical company assures that the preclinical results “have shown that it gives very good protection against the coronavirus because it prevents the replication of the virus at different levels of the respiratory tract.”

Two-dose coronavirus vaccine

In statements to Efe Alberto Borobia, researcher of the Clinical Pharmacology service and the Central Unit for Clinical Research and Clinical Trials (UCICEC) of the Hospital de La Paz, pointed out that once the two doses have been supplied to all volunteers, low doses of vaccine “to simulate an infection and evaluate whether or not the organism of the volunteer generates neutralizing antibodies against those antigens that have been injected”.

“You do not cause an infection since it is a vaccine that is not from a virus, it is not from the attenuated virus, but it is a genetically modified organism, it is an adenovirus in which one of the proteins of the virus is inserted into one of its sequences. coronavirus ”, explained Borobia, who has commented that this entire procedure takes 14 and 16 months.

Under normal conditions, the conclusion of phase 2 of the trial would be awaited for phase 3 to begin, which consists of evaluating the efficacy of the drug, and the term for the vaccine to be ready would be “between one and two years” .

Adenovirus-based covid-19 vaccine

In addition to Spain, the trial will take place in two other European countries, Belgium and Germany. Phase 1 has been done in the United States and Belgium. A total of 550 healthy volunteers from the three European countries will participate to evaluate the range of doses and the different administration guidelines.

This vaccine, called Ad26.COV2.S, uses a technology based on a non-replicative recombinant adenovirus to generate an immune response against one of the coronavirus proteins. Trials are essential to guarantee the quality, safety and efficacy of vaccines, the Ministry of Health reported in a statement.

From Distefar we want to send our support to the professionals of the La Paz, La Princesa and Marqués de Valdecilla hospitals to carry out this trial.

Related entries

4 October, 2023

“Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.


Leer más
2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más

Recent Posts

  • “Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.
  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.